# S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

> **NCT00946712** · PHASE3 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 1333 (actual)

## Conditions studied

- Recurrent Large Cell Lung Carcinoma
- Recurrent Lung Adenocarcinoma
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Large Cell Lung Carcinoma
- Stage IV Lung Adenocarcinoma
- Stage IV Squamous Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Cetuximab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00946712
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07-15
- **Primary completion:** 2017-08-31
- **Final completion:** 2022-02-08
- **Target enrollment:** 1333 (ACTUAL)
- **Why stopped:** terminated at pre-planned futility analysis
- **Last updated:** 2023-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946712, "S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00946712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*